NCT02386800 2026-03-16CINC424A2X01B Rollover ProtocolNovartisPhase 4 Active not recruiting279 enrolled
NCT04710576 2026-03-16AGAVE-201Syndax PharmaceuticalsPhase 2 Active not recruiting241 enrolled 11 charts 1 FDA
NCT03229200 2025-10-30Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.Pharmacyclics Switzerland GmbHPhase 4 Active not recruiting297 enrolled
NCT01744223 2022-07-12Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell TransplantBellicum PharmaceuticalsPhase 1/2 Active not recruiting36 enrolled